Back to Hematology
Hematologyv2016Evidence-Based

International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI)

Stratifies chronic lymphocytic leukemia patients into four risk categories based on five independent prognostic factors. The CLL-IPI combines genetic (TP53 status, IGHV mutational status), biochemical (β2-microglobulin), and clinical parameters (age, clinical stage) to predict overall survival and treatment outcomes. This validated prognostic model discriminates four risk groups with significantly different 5-year overall survival rates: low risk (93.2%), intermediate risk (79.3%), high risk (63.3%), and very high risk (23.3%). The CLL-IPI enables more targeted patient management and risk-adapted treatment strategies in clinical practice and clinical trials.

Clinical Input Parameters

mg/L
years
Clinical Assessment
Awaiting Parameters
cll ipi score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Score = TP53 abnormal (4) + IGHV unmutated (2) + β2-microglobulin >3.5mg/L (2) + Advanced stage (1) + Age >65 years (1)

Clinical Pearls & Practice Notes

  • The CLL-IPI was developed from a meta-analysis of individual patient data from 8 studies including 3472 patients
  • Scoring parameters: TP53 abnormal (4 points), IGHV unmutated (2 points), β2-microglobulin >3.5 mg/L (2 points), Advanced clinical stage (1 point), Age >65 years (1 point)
  • TP53 abnormalities include del(17p) and/or TP53 mutation detected by FISH or sequencing
  • IGHV mutated is defined as <98% homology to germline sequence (favorable prognosis)
  • IGHV unmutated is defined as ≥98% homology to germline sequence (unfavorable prognosis)
  • β2-microglobulin normal ≤3.5 mg/L, elevated >3.5 mg/L (some labs use 3.0 mg/L cutoff)
  • Early stage: Binet A or Rai 0; Advanced stage: Binet B-C or Rai I-IV
  • Age cutoff is 65 years (≤65 years vs >65 years)
  • Four risk groups: Low (0-1), Intermediate (2-3), High (4-6), Very High (7-10)
  • 5-year OS rates: Low 93.2%, Intermediate 79.3%, High 63.3%, Very High 23.3%
  • The CLL-IPI predicts overall survival and has been validated for time to first treatment
  • Use for risk stratification and patient counseling, not for determining need for treatment
  • Treatment decisions should be based on iwCLL (International Workshop on CLL) criteria
  • The index remains prognostically relevant in the era of targeted therapies
  • Consider clinical trial enrollment for high and very high risk patients
  • Genetic testing for TP53 and IGHV should be performed before treatment initiation
  • β2-microglobulin reflects tumor burden and is routinely available in clinical practice
  • The CLL-IPI has been validated across different geographic regions and treatment eras
  • Risk stratification guides treatment intensity and monitoring frequency
  • Regular reassessment may be appropriate as disease evolves over time

Evidence & Literature Citations

  1. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016 Jul;17(7):779-90. doi: 10.1016/S1470-2045(16)30029-8.
  2. Condoluci A, Terzi di Bergamo L, Langerbeins P, et al. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020 May 28;135(22):1859-1869. doi: 10.1182/blood.2019003453.
  3. Gentile M, Shanafelt TD, Rossi D, et al. Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. Blood. 2016 Oct 13;128(15):2093-2095. doi: 10.1182/blood-2016-07-728261.

Score Interpretation Ranges

Low Risk0 – 1 pts

Score 0-1 points

Intermediate Risk2 – 3 pts

Score 2-3 points

High Risk4 – 6 pts

Score 4-6 points

Very High Risk7 – 10 pts

Score 7-10 points

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.